= 17 nM); displays selectivity for GSK-3β
over CDK2 (22% inhibition at 10 μ
M). Increases liver glycogen reserves in rodents. Brain penetrant.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening.
Khanfar et al.